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Abstract
Background: Induction of HIV-1-specific T-cell responses relevant to diverse subtypes is a major goal of HIV vaccine
development. Prime-boost regimens using heterologous gene-based vaccine vectors have induced potent, polyfunctional T
cell responses in preclinical studies.
Methods: The first opportunity to evaluate the immunogenicity of DNA priming followed by recombinant adenovirus
serotype 5 (rAd5) boosting was as open-label rollover trials in subjects who had been enrolled in prior studies of HIV-1
specific DNA vaccines. All subjects underwent apheresis before and after rAd5 boosting to characterize in depth the T cell
and antibody response induced by the heterologous DNA/rAd5 prime-boost combination.
Results: rAd5 boosting was well-tolerated with no serious adverse events. Compared to DNA or rAd5 vaccine alone,
sequential DNA/rAd5 administration induced 7-fold higher magnitude Env-biased HIV-1-specific CD8
+ T-cell responses and
100-fold greater antibody titers measured by ELISA. There was no significant neutralizing antibody activity against primary
isolates. Vaccine-elicited CD4
+ and CD8
+ T-cells expressed multiple functions and were predominantly long-term (CD127
+)
central or effector memory T cells and that persisted in blood for .6 months. Epitopes mapped in Gag and Env
demonstrated partial cross-clade recognition.
Conclusion: Heterologous prime-boost using vector-based gene delivery of vaccine antigens is a potent immunization
strategy for inducing both antibody and T-cell responses.
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Introduction
Most viral vaccines provide protection at least partially through
the induction of neutralizing antibodies [1,2]. For HIV, such
antibodies have proven difficult to elicit [3,4], and prior efficacy
trials of products that did not stimulate neutralizing antibodies
failed to show protection [5,6,7,8]. Therefore, vaccine induction of
potent, long-lived CD8
+ T cells has become a major goal of
current HIV-1 vaccine efforts [9]. This concept is supported by
data showing that CD8
+ T cell responses are associated temporally
with reduction of viral load after acute infection [10,11], specific
MHC class I alleles are associated with slower progression of
HIV/AIDS [12,13], CD8
+ T cells are largely responsible for
controlling SIV viremia [14,15], and mutation of dominant CD8
+
T cell epitopes is a major mechanism of immune escape in HIV
and SIV infection [16,17].
Some vaccine platforms induce high frequencies of HIV-specific
CD4
+ and CD8
+ T cells [18,19,20,21]. SIV-specific T cell
responses induced by such platforms do not protect monkeys
against high dose SIV challenge, but do protect against high
plasma viral burdens and loss of peripheral, and more importantly,
gut-associated CD4
+ memory T cells, leading to prolonged
survival [22,23]. While this protection has most often been
demonstrated in monkeys challenged with homologous virus (a
SIV strain that matches the vaccine insert), an HIV vaccine will
need to protect against the wide diversity of circulating clades of
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the T cell response generated by a vaccine, not only in terms of the
number of epitopes targeted, but also the ability of epitope-specific
responses to accommodate clade-specific viral diversity.
T cells differ in their phenotype and function, and evidence
suggests that these differences can impact protection against
pathogens that are controlled by T cells. Non-progressive HIV
infection is associated with CD8
+ T cells that elaborate more
simultaneous functions (termed polyfunctional) than is seen in
progressive infection [24], and the surface phenotype of T cells
may be linked to certain functions that may be important for
protection. For example, expression of CD57 on CMV-specific
CD4
+ T cells is associated with MIP-1b production and direct
cytolytic activity of these cells [25]. Therefore, it is important to
consider both the phenotype and function of vaccine-induced T
cells when evaluating their protective potential.
Here we describe the induction of HIV-1-specific antibody and T
cell responses in subjects primed by DNA immunization with plasmids
expressing envelope (env) genes from clades A, B, and C, and gag, pol,
and nef genes from clade B [19,20], and boosted with recombinant
adenovirus serotype 5 (rAd5) vectors expressing matching genes but
lacking nef [18]. We specifically address the phenotype, function,
longevity, epitope breadth, and functional avidity of the vaccine-
elicited immune response in order to better characterize the protective
potential of a DNA prime, rAd5 boost vaccine regimen.
Methods
Ethics Statement
These studies were approved by the National Institute of Allergy
and Infectious Diseases Institutional Review Board, and were
performed in accordance with 45 CFR Part 46, U.S. Food and
Drug Administration regulations, and principles expressed in the
Declaration of Helsinki. All subjects signed written informed
consent documents.
Objectives
To characterize the magnitude, phenotype, function, breadth,
and durability of the T cell response induced by DNA priming and
rAd5 boosting compared to either vaccine modality given alone. A
secondary objective was to characterize the antibody responses
elicited by the DNA prime-rAd5 boost regimen. The protocols for
this trial and supporting CONSORT checklist are available as
supporting information; see Checklist S1, Diagram S1, Protocol S1
(VRC 009), and Protocol S2 (VRC 010).
Participants
Prior recipients of candidate HIV DNA vaccines from VRC
004 (evaluation of a 4-plasmid DNA product) [20] and VRC 007
(evaluation of a 6-plasmid DNA product) [19] who consented to
do so were assessed for eligibility to participate in a study
evaluating a booster immunization with rAd5 [18]. Ultimately 10
subjects from VRC 004 enrolled in VRC 009 and 4 subjects from
VRC 007 enrolled in VRC 010 (Table 1).
Study Design
Studies VRC 009 (NIH 05-I-0081) and VRC 010 (NIH 05-I-
0140) were Phase I, open-label, ‘‘rollover’’ studies of a booster
injection of the VRC multiclade recombinant adenoviral vector
serotype 5 (rAd5) vaccine, VRC-HIVADV014-00-VP, adminis-
tered to HIV-uninfected, healthy subjects who had previously
received three injections of the multiclade DNA vaccine, VRC-
HIVDNA009-00-VP at either the 4 mg or 8 mg dosage in study
VRC 004 (03-I-0022) [20] or of the multiclade DNA vaccine,
VRC-HIVDNA016-00-VP at a 4 mg dosage in study VRC 007
(04-I-0254) [19], respectively. The interval between prior DNA
immunization and rAd5 boosting varied greatly and was not used
as a criterion to exclude anyone from enrollment in the roll-over
studies. Subjects from both 4 mg and 8 mg dose cohorts in VRC
004 were included because earlier work had shown no significant
differences in the frequency, magnitude or quality of response to
primary DNA immunization between dose levels [20]. Subjects
were administered a single 10
10 PU rAd5 vector vaccination as a
1 mL intramuscular (deltoid) injection on the day of enrollment
(Day 0). Studies were conducted at the National Institutes of
Health (NIH) Clinical Center, Bethesda, MD by the Vaccine
Research Center (VRC), NIAID, NIH, DHHS. Subjects from
VRC 006 [18], which evaluated rAd5 only immunization, were
used as a parallel cohort for comparison to subjects in the VRC
009 and 010 protocols. The 10 subjects in VRC 006 who received
a single 10
10 PU IM injection of the rAd5 vaccine were enrolled
between 8/23/04 and 9/15/04. The same clinical staff enrolled
subjects from all studies, and the same laboratory staff processed
and analyzed samples with identical methodology. VRC 009 and
VRC 010 were open-label and unblinded, while VRC 006
included placebo recipients and was double-blinded.
Vaccine
The VRC-HIVADV014-00-VP vaccine is a 3:1:1:1 ratio of
recombinant replication-defective adenoviral vectors that encode
for clade B HIV-1 Gag-Pol polyprotein and Env glycoproteins
from clades A, B, and C, respectively. The vector is designed to be
E1, E3, and E4 deleted, and express the recombinant gene from
the E1 position in the adenovirus genome, and is produced in 293-
ORF6 cells [26]. Study supplies were manufactured under current
Good Manufacturing Practices (cGMP) and tested in compliance
with current FDA guidance for safety, purity, potency, identity
and quality before release [18].
Peptides
Peptides (15-mers overlapping by 11) matching the sequences of
the HIV-specific antigens expressed by the vaccines were used at
.70% purity. They were pooled according to antigen (EnvA, EnvB,
EnvC,Gag,Pol,Nef), orwere pooled in a separate matrixformat (see
epitope mapping methods), and were used at a final concentration of
2.5 mg/ml to stimulated vaccine-induced T cells in vitro.
Enzyme-Linked Immunospot Assays (ELISpot)
The frequency of antigen/vaccine-specific cells was determined
as previously described [20]. Cryopreserved PBMCs were
Table 1. Eligibility and enrollment process.
N
Consented to be assessed for eligibility 20
from VRC 004 (4-plasmid DNA recipients) [20] 11
from VRC 007 (6-plasmid DNA recipients) [19] 9
Excluded 6
not interested 1
not eligible 5
Enrolled 14
VRC 009 10
VRC 010 4
doi:10.1371/journal.pone.0009015.t001
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vaccine antigens. IFN-c ELISpot was performed using a
commercial kit (BD Biosciences), read on a CTL ELISpot image
analyzer (Cellular Technology Ltd; Cleveland, OH), and ex-
pressed as mean spot-forming cells (SFC) per million PBMC.
Flow Cytometric Analysis
Cryopreserved PBMCs were stimulated by peptide pools for
6 hours with brefeldin A. For routine analyses permeabilized fixed
cells were evaluated by flow cytometry for expression of CD3,
CD8, CD4, and IFN-c and/or IL-2, then analyzed using FlowJo
software (TreeStar; Ashland, OR) as previously described [20].
The following antibodies were used in various combinations to
evaluate multiple functions and phenotypes of vaccine-induced T
cells: CD3-Cy7APC, IFN-c-FITC, IL-2-APC, TNFa-Cy7PE,
MIP-1b-PE (BD Pharmingen; San Diego, CA); CD4-Cy5.5PE
(Caltag; Burlingame, CA); CD127-PE, CD27-CY5PE, CD45RO-
TRPE (Beckman Coulter; Miami, FL); PD-1-Biotin (R&D
systems, Minneapolis, MN); V-amine dye (Invitrogen; Eugene,
OR); CD14-PACBL, CD19-PACBL, CD8-QD705, CCR7-
Alexa680, Streptavidin-QD655, and CD57-QD545 (conjugated
according to standard protocols http://drmr.com/abcon/index.
html). Unconjugated antibodies were obtained from BD Pharmin-
gen and R&D Systems. Q-Dots, Alexa 680, and Pacific blue were
obtained from Invitrogen; Cy5, Cy5.5, and Cy7 were obtained
from Amersham Biosciences (Pittsburgh, PA) and PE and APC
from ProZyme (San Leandro, CA). Cells were collected on an
LSR II instrument (BD Immunocytometry Systems) configured to
detect 18 fluorochromes, 350,000–1,000,000 events were collected
per sample, and analysis was performed using FlowJo software
version 8.4 (TreeStar). After gating, Boolean combinations of
single functional gates were then created using FlowJo software to
determine the frequency of each response based on all possible
combinations of cytokine expression or all possible combinations
of differentiation marker expression. Background responses
detected in negative control tubes were subtracted from those
detected in stimulated samples for every specific functional
combination. The MFI of each functional parameter was also
determined for all Boolean gate combinations using FlowJo
software. Frequency and MFI data were processed using Pestle,
version 1.5.4, Mario Roederer, Vaccine Research Center, NIAID,
NIH.
Epitope Mapping
The software program ‘‘Deconvolute This’’ was used to create
sets of pooled peptides, such that each peptide from the
overlapping 15-mers (derived from the three envs, gag, pol, and nef
antigens contained in the vaccine) is present in five different pools.
This 5-fold coverage is optimal for deconvolution of individual
responses from this set of 869 individual peptides [27]. Peripheral
blood samples were subjected to ELISpot assays using this peptide
matrix to determine the number of 15-mer peptides targeted after
the rAd5 boost. Targeting of two overlapping peptides was
arbitrarily considered to represent a single epitope. Where cell
numbers permitted, shorter peptides were used to map the
minimal epitope, and ICS was used to determine the phenotype
(CD4 vs CD8) of the response.
Functional Avidity
Five serial ten-fold dilutions (5.0 to 0.0005 mg/ml) of optimally-
defined peptide epitopes were used to stimulate responses in the
IFN-c ELISpot assay. Log-linear regression curves were used to
determine the peptide concentration which gave half-maximal
number of SFCs, and this concentration was taken as the
functional avidity of the response.
Measurement of Antibody Responses
Standardized research ELISAs were performed to delineate the
antibody response to viral antigens encoded within the vaccine.
End-point titers of antibodies were determined using 96-well
Immulon2 (Dynex Technologies) plates coated with a preparation
of purified recombinant HIV proteins derived from the same
sequences as the vaccine antigens [20]. End-point titer was
calculated as the most dilute serum concentration that gave an
optical density reading of .0.2 above background. Subjects were
screened via a commercial EIA (Abbott Laboratories HIV-1/
HIV-2 rDNA) and Western blot (Mayo Laboratory, Genetic
Systems Western blot kit by BioRad Laboratories, Inc).
Serum neutralizing antibody levels were measured using single
round replication-defective Env-pseudoviruses and an engineered
cell line that expresses luciferase upon viral infection. The methods
and virus strains were previously described [28,29].
Data Analysis and Statistics
The statistical methods followed the same conventions that were
used for the predecessor studies and were done post hoc. Measures
of positive T-cell response are defined by both a statistical test and
a minimum magnitude threshold. Specifically, for ELISpot, a
positive response is defined as at least 50 SFC per million PBMC
and a p-value of ,.05 on a permutation test using a Westfall-
Young correction for multiple comparisons [30]. For ICS, a
positive response was defined as one with a p-value of ,0.01 from
a Fisher’s Exact Test with a Holm adjustment for multiplicity and
a background-subtracted magnitude of at least 0.0241 for CD4
+ or
0.0445 for CD8
+. The cutoff values for ELISpot and ICS were
defined as the 99
th percentile of 34 HIV-negative samples
stimulated with 8 different peptide pools (272 different stimula-
tions) [18]. For ELISA, a positive response is defined as any
measure with end-point titer $30. All paired comparisons were
done using Wilcoxon Signed Rank tests (post-DNA response
compared to rAd5 vector boosting). Unpaired comparisons were
conducted using Wilcoxon Rank Sum tests (DNA/rAd5 recipients
compared to historical controls immunized with rAd5 vector only).
The data analysis program, Simplified Presentation of Incred-
ibly Complex Evaluations (SPICE, version 4.1.5, Mario Roederer,
Vaccine Research Center, NIAID, NIH) was used to analyze and
generate graphical representations of T cell responses detected by
polychromatic flow cytometry. All values used for analyzing
proportionate representation of responses are background-sub-
tracted. Hence, these values can be less than zero, in cases where
the background sample had more events in a particular functional
gate than the positive.
Results
Study Design and Volunteer Demographics and Safety
Subjects from prior studies of experimental DNA vaccines, 10 of
32 (31%) available subjects from VRC 004 [20] enrolled in VRC
009 between 1/28/2005 and 7/25/05, including 5 subjects each
from the 4 mg and 8 mg groups in VRC 004, and four of 14
(29%) available subjects from VRC 007 [19] enrolled in VRC 010
between 5/11/05 and 6/16//05. The demographics of the study
subjects are shown in Table S1. The interval between the first dose
of DNA vaccine and the rAd5 vector booster immunization
ranged from 79–109 weeks (mean=94 weeks) for the ten VRC
009 participants, and was 32–37 weeks (mean=35 weeks) for the
four VRC 010 participants. All subjects were followed for the
Immune Responses to DNA/rAd
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Demographic, reactogenicity, and HIV seroconversion data are
recorded in Tables S1, S2, and S3. There were no serious adverse
events.
T Cell Responses
All 14 subjects (100%) met the positivity criteria for ELISpot
responses to at least one of 6 gene-specific peptide pools after rAd5
vector boost (EnvA, EnvB, EnvC, Gag, Pol, or Nef). One subject
responded to 6 pools, 4 responded to 5 pools, and 5 responded to 4
pools. By combining the highest response to an Env with the
responses to Gag, Pol, and Nef the total ELISpot response after
rAd5 vector boost ranged from 195 to 4548 SFC/million PBMCs
with a median of 891. The median magnitude of the total ELISpot
response after rAd5 vector boosting was 4.5-fold higher than the
total ELISpot response following DNA priming (p,.001)
(Figure 1A) among the same set of volunteers, and 6-fold higher
than rAd5 vector only immunized historical controls (p=.002)
[18]. The total ELISpot response dropped to a median value of
370 SFC/million PBMCs (range 120–3371) by 3 months after
rAd5 vector boost and then was sustained at a relatively constant
level for the remainder of the 24 week observation period (data not
shown). Overall the greatest response to single peptide pool was to
EnvA with peak responses following the rAd5 vector boost ranging
from 90 to 3682 SFC/million PBMCs. However, median Gag
responses after the rAd5 vector boosting were also significantly
higher than after DNA (p,.001) or rAd5 (p,.001) and ranged
from 28 to 797 SFC/million PBMCs. Longitudinal plots
demonstrate the increased magnitude of response post rAd5
vector boosting, followed by a reduction in magnitude to a stable
response maintained beyond 6 months (Figure 1B). The peak
EnvA-specific response post rAd5 vector boost is plotted as the
mean of the 2, 4, and 6 week data.
CD4
+ T cell responses measured by ICS for IFN-c and/or IL2
were detected after stimulation with at least one peptide pool, each
pool representing a single gene product, in 13/14 subjects after
rAd5 vector boosting. Two subjects responded to 6 gene product
pools, four responded to 5 pools, one responded to four peptide
pools, and six responded to three (data not shown). Combining the
responses to the distinct gene-specific peptide pools, the summed
(best Env + Gag + Pol + Nef) CD4
+ T cell ICS response after rAd5
vector boosting ranged from 0.065 to 0.69% of total CD4
+ T cells,
with a median of 0.22%. The median magnitude of the total CD4
+
T cell ICS response 4 weeks following rAd5 vector boosting was
about the same as detected in rAd5 vaccine-only immunized
historical controls [18]. The magnitude of peak CD4
+ T cell ICS
response to EnvA after rAd5 vector boosting ranged from 0 to 0.45
percent of total CD4
+ T cells and was stable and persisted at a
constant level for the remainder of the 6 month follow-up period.
Unlike the ELISpot and CD8
+ T cell responses, the magnitude of
CD4
+ T cell responses was not elevated significantly after the rAd5
vector boosting (Figure 1C).
CD8
+ T cell responses measured by ICS for IFN-c and/or IL-2
were detected after stimulation with at least one gene-specific
peptide pool in 10 subjects after rAd5 vector boosting. Two
subjects responded to 5 pools, one responded to 4 pools, and four
responded to 3 pools (data not shown). The summed CD8
+ T cell
ICS response after rAd5 vector boost ranged from 0.02 to 2.32%
of total CD8
+ T cells, with a median of 0.25%. The median
magnitude of the total CD8
+ T cell ICS response following rAd5
vector boosting was 7-fold higher than the total CD8
+ T cell ICS
response after DNA priming (p,.001) (Figure 1D), and 5-fold
higher than rAd5 vector only immunized historical controls
(p=.057) [18]. The total CD8
+ T cell ICS response dropped to a
median value of 0.15% total CD8
+ T cells (range 0.003–2.04) by 3
months after rAd5 vector boost and then was sustained at a
constant level for the remainder of the 6 month follow up period.
The magnitude of peak response by CD8
+ T cell ICS ranged from
0.01 to 1.53% of total CD8
+ T cells to EnvA; longitudinal plots of
the EnvA-specific response demonstrate that the increase in CD8
+
T cell responses after rAd5 vector boosting correlates with the
increase in ELISpot responses (Figure 1). The Gag-specific
response after rAd5 boosting ranged from 0 to 0.57% of total
CD8
+ T cells and was significantly higher than after DNA alone
(p=.004), and it trended higher than after rAd5 only, but did not
reach statistical significance (p=.291).
The magnitude of the IFN-c ELISpot response after rAd5 boost
correlated with the magnitude of those measurements after DNA
priming (p=.001 by Spearman non-parametric test). There was
also a suggestion of a correlation between CD8
+ T cell ICS
responses after the rAd5 boost and after the DNA prime, but this
did not reach statistical significance (p=.061) This suggests
effective DNA priming was an important determinant of the
response to rAd5 boosting.
Phenotype of Responding Cells
We used a 13-color immunophenotyping panel to characterize
the antigen-specific T cells induced by the vaccine. Cryopreserved
specimens for all individuals at four different time points were
assessed (4 weeks following the last DNA immunization; 6–18
months later, immediately prior to rAd5 boosting; 4 weeks after
rAd5 boosting; and 6 months following rAd5 boosting). These
represent the ‘‘effector’’ and ‘‘memory’’ time points following the
priming and boosting stages. Included in the panel were reagents
to identify T cell lineages (CD3
+CD4
+ or CD3
+CD8
+), responding
cells (IFN-c
+ or IL-2
+ or TNF
+), as well as memory/differentiation
stages (CD127, CCR7, CD57, PD-1, CD27, and CD45RO).
Figure 2A illustrates the ‘‘gating tree’’ used to identify the
responding cells, and a representative example of the phenotypes
of these responding cells compared to the entire CD4
+ or CD8
+ T
cell population. Responding cells had a phenotype associated with
memory cells.
The expression of the six differentiation markers on vaccine-
induced T cells is shown in Figure 2B, as a function of time.
CD127 expression was uniform on Env-specific CD4
+ T cells, and
on most Env-specific CD8
+ T cells, suggesting that the vaccine-
induced T cells are long-lived memory cells capable of homeostatic
expansion [31]. CD4
+ T cells tended to express more markers
associated with being ‘‘central memory’’ (CCR7 and CD27)
[32,33]; CD8
+ T cells appear to be more differentiated. Indeed,
within the CD8
+ population, 20–30% expressed CD57, a
phenotype consistent with terminal effector cells [34]. Within
either lineage, about half of the cells expressed PD-1. Consistent
with the fact that antigen stimulation induces PD-1 expression on
activated T cells, the expression of this marker declined mildly
over time after DNA or rAd vaccination. In contrast, there was
little change in the expression of the other phenotypic markers on
the antigen-specific cells over time.
We further characterized the differentiation stages of the
responding T cells as falling into central memory (TCM), effector
memory (TEM), or terminal effector (TEF) stages. The original
definition of these differentiation stages is derived from the
measurement of CCR7 and CD45RO [33]; however, others have
used CD27 and CD45RO to assign these stages [32,35]. In
Figure 2C, both phenotypic characterizations are shown for the
vaccine-induced T cells. Within the CD4
+ subset, the cells are
strongly biased towards TCM cells; the representation within the
different subsets does not change at all over time. Within CD8
+ T
Immune Responses to DNA/rAd
PLoS ONE | www.plosone.org 4 February 2010 | Volume 5 | Issue 2 | e9015Figure 1. T cell responses to DNA are boosted by rAd immunization. (A) IFN-c ELISpot responses in subjects 4 weeks after third dose of DNA
or after a single dose of rAd5 vector only compared to peak response at 4–6 weeks following rAd5 vector boosting. The scale indicates spot-forming
cells per million peripheral blood mononuclear cells. Individual subject responses are shown for recipients of 4-plasmid (VRC 004) or 6-plasmid (VRC
007) vaccines (left panel), the rAd5 vector (VRC 006) vaccine (center panel), and the combined DNA/rAd5 prime-boost (right panel). Results for
peptide pool stimulation are shown for each peptide pool representing a single gene product in the vaccine shown on the x-axis. Boxplots represent
the median and IQR. Longitudinal T cell responses to EnvA peptides were measured by IFN-c ELISpot (B), CD4
+ (C) and CD8
+ (D) ICS and data are
shown for all 14 subjects. The line graph shows the mean response at each time point. Some clinical time points were aggregated and are shown
here as the mean value of the measurements for the grouped time points: The data following DNA injections #2 and #3 are the means of results
from 2 and 4 weeks after the immunization time point; 6 month data post-DNA are the means of results from 16, 24, and 30 weeks after DNA
injection #3; and the ,6 week post-rAd5 time point data are means of results from 2, 4, and 6 weeks after rAd5 vector immunization.
doi:10.1371/journal.pone.0009015.g001
Immune Responses to DNA/rAd
PLoS ONE | www.plosone.org 5 February 2010 | Volume 5 | Issue 2 | e9015Figure 2. Phenotype of vaccine-induced T cells. (A) Flow cytometric analysis of antigen-specific T cells. The top row of graphs shows the
progressive gating to identify live CD3
+CD4
+ or CD3
+CD8
+ lymphocytes. For either CD4 or CD8 T cells, antigen-responsive cells (following in vitro
stimulation) are identified by the production of IL2, IFN-c, or TNF. This example shows EnvA-stimulated cells from one of the highest responders in
the study; the phenotyping graphs illustrate the distribution of cells that make any cytokine (blue) overlaid on the total CD4 or CD8 population (grey).
(B) The distribution of expression of a variety of cell surface markers on antigen-specific CD4 or CD8 T cells following vaccination. The colored bars
represent the IQR for the distribution at different time points: 4 weeks post-DNA (blue); 6–18 months post DNA (red); 4 weeks post rAd5 boost
(green); and 6 months post-boost (orange). (C) Two different phenotyping schemas, based on either CD27 or CCR7 expression in combination with
CD45RO, were used to characterize antigen-specific T cells. The bar charts show the individual data points and IQR for the four time points following
immunization. The pie charts summarize these distributions, showing the average proportion of the CD4 or CD8 vaccine-specific T cell response that
is TCM (light grey), TEM (medium grey), or TEF (black). Asterisks indicate distributions that are different from the earliest time point (4 weeks post DNA)
at p,0.05 (Student’s T test).
doi:10.1371/journal.pone.0009015.g002
Immune Responses to DNA/rAd
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increase of TEF and a concomitant decrease of TCM (or TEM) over
time.
Quality of Responding Cells
The quality of a T cell response can be characterized in part by
the patterns of cytokine production. We have previously shown
that T cells can be divided into those that make only one cytokine
(monofunctional), two cytokines, or multiple cytokines simulta-
neously (polyfunctional). The vaccine regimen induced polyfunc-
tional T cells in both the CD4
+ and CD8
+ lineages (Figure 3). The
CD4
+ T cells were highly polyfunctional, in that a majority
produced all three cytokines, and less than 25% were monofunc-
tional. CD8
+ T cells were predominantly IFN-c
+ and either TNF
+
or TNF
2. There was a trend towards increasing functionality in
the CD8
+ T cells after rAd boosting, as evidenced by the
decreasing proportion of monofunctional T cells.
Recent reports show that the amount of cytokine produced by
individual antigen-specific T cells can vary dramatically depending
on how they were elicited [36,37]; those cells with the highest per-
cell production are optimized for effector activity and protection.
The cytokine production can be estimated by the median
fluorescence intensity (MFI) of the cytokine staining for the
responding cells. For the vaccine-induced T cells, we observe a
consistent and dramatic increase in the IFN-c and TNF MFIs for
polyfunctional cells compared to less functional cells (Figure S1). In
addition, we observe that the IFN-c MFI for CD4
+ polyfunctional
cells increases substantially after rAd5 boosting (Figure S1B). This
Figure 3. Function of vaccine-induced T cells. The quality of the vaccine-elicited CD4 or CD8 T cell response is characterized by the proportion
of cells making every possible combination of the three measured cytokines. The bar charts show the individual data points and IQR for four time
points following immunization. Pie charts show the average proportion of the CD4 or CD8 vaccine-specific T cell response that is polyfunctional
(black), producing two functions (medium grey), or is monofunctional (light grey). The memory time point had a significantly different quality of CD8
T cell response than earlier time points (SPICE permutation analysis).
doi:10.1371/journal.pone.0009015.g003
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prime/boost exhibit better effector function than cells primed by
DNA alone.
Quality and Phenotype
Since our immunophenotyping panel included both the
functional measurements as well as the memory/differentiation
measurements, we could begin to assess the relationship of
function to differentiation stage. The complexity of this analysis
is enormous, as the number of potential distinct phenotypes
(2
6=64) and functional states (2
3=8) to be analyzed in
combination, for both CD4
+ and CD8
+ T cells, well exceeds the
statistical power of this relatively small sample set. We therefore
restricted our current analysis to determine the quality of the
response within TCM,T EM, and TTE subsets (defined on the basis
of CCR7 and CD45RO expression). As shown in Figure 4, the
most polyfunctional subsets within both the CD4
+ and CD8
+
lineages belong to the TCM subset. In contrast, the TEM (and TEF)
subsets are highly enriched for the IFN-c
+TNF
+ or IFN-c
+ cells,
particularly within CD8
+ T cells.
Breadth of the T Cell Response
Epitope mapping was carried out on nine of the volunteers from
VRC 009. Between one and ten epitopes were mapped in each
volunteer, with an average of 3.33 epitopes per volunteer (Table 2).
Where cell numbers permitted, several further studies were done
to characterize the targeted epitopes. Intracellular cytokine
staining was performed to determine whether the response was
mediated by CD4
+ or CD8
+ T cells, shorter peptides were used to
map the minimum epitope, and peptide titrations were performed
with the minimum epitope to determine the functional avidity of
the response (peptide concentration giving half-maximal response).
In many cases previously-described epitopes with known HLA
restrictions were mapped in these vaccine volunteers. Among the
known epitopes that were targeted were the A03-restricted
responses to TVYYGVPVWK and RLRPGGKKKY in envelope
(EnvTK10 and EnvRY10, respectively), the B57-restricted
response to TSTLQEQIGW in Gag (GagTW10), and the A29
or A32-restricted response to RIKQIINMW in envelope
(EnvRW9) [38].
Regions previously not known to contain CD4
+ and CD8
+ T
cell epitopes were also identified, such as a CD8
+ T cell epitope in
envelope CAPAGFAIL (EnvCL9). It should also be noted that we
often found a lower magnitude of response when we mapped
down to the minimum epitope, suggesting that there may be other
overlapping epitopes within some of our 15-mer responses that we
have failed to further characterize. This suggests that our methods
underestimate the number of epitopes targeted in these volunteers.
Cross-Clade Recognition
We next investigated to what extent the epitope-specific
responses elicited by the vaccine would cover the sequence
variability within isolates from clades A, B, C and D. Peptides
corresponding to the major clade A, B, C, and D variants were
synthesized for five minimum epitopes in Gag and Env. These
were used in ELISpot assays at multiple different concentrations to
determine the recognition patterns for the vaccine-elicited
responses to these five epitopes (Figure 5). In all except one
instance, we were able to test the recognition (at least against the
predominant sequence) after DNA priming, and again after rAd5
boosting.
A wide range of epitope-specific functional avidities was evident,
with some epitopes (EnvCL9 and EnvRY10) inducing IFN-c
production only at the highest peptide concentration (5 mg/ml,
Figure 5B and G) while others (EnvTK10) were active out to very
low peptide concentrations (5 ng/ml, Figure 5E and F). Three of
the four responses that were tested after DNA priming (EnvCP9,
EnvRW9, and EnvTK10) were detectable at that time point
(Figure 5A, B, E, and F), and in all cases the frequency of those
responses increased after the rAd5 boost. While the boost
augmented the frequency of the responses, it did not appear to
have a major impact on either the functional avidity, or the
recognition pattern of the epitope variants. The responses against
the B57-restricted epitope GagTW10 were not detectable after the
DNA prime in two volunteers (Figure 5C and D) but were readily
detectable after the boost.
Where more than one volunteer had a detectable response
against a given epitope, the functional avidities and patterns of
Figure 4. The quality of the response within TCM,T EM,o rT EF cells.
Data for each subject is averaged over time points (there was no
statistically significant change in quality over time within each subset). TCM
cells have significantly more polyfunctional T cells than TEM or TEF cells.
doi:10.1371/journal.pone.0009015.g004
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Antigen Peptide Sequence* ELISpot (SFC/10
6 PBMC) Functional avidity (mg/ml)** ICS*** HLA****
Subj A (A01, A26, B5601, B57, Cw1, Cw6)*****
EnvA CAPAGFAIL 1220 0.0135 CD8 ND
EnvB MRVKEKYQHLWRWGW 3640 CD8
EnvB DAKAYDTEVHNVWAT 840
EnvB RIKQIINMW 2035 ND CD8 ND
GagB TSTLQEQIGW 425 0.548 CD8 B57
Subj C (A02, A03, B07, B15, Cw3, Cw7)
EnvA AVYYGVPVWK 2150 0.060 CD8 A03
EnvA AMYPPPIQGVIRCES 550
EnvB TVYYGVPVWK 2550 0.0006 CD8 A03
Subj D (A02, A31, B15, B44, Cw3, Cw5)
EnvA AMYPPPIQGVIRCES 98
EnvC PGQTFYATGDIIGDI 126
GagB IVKCFNCGKEGHTAR 116
Subj E (A01, A03, B07, B7301, Cw7, Cw15)
EnvA LWVAVYYGVPVWKDA 71 A03
Subj F (A03, A32, B07, B55, Cw3, Cw7)
EnvB
EnvB
KLWVTVYYGVPVWKE
TVYYGCPVWKEATTT
68
35
A03
Subj G (A03, A24, B15, B35, Cw3, Cw4)
EnvA LWVAVYYGVPVWKDA 1315 A03
EnvA
EnvA
CNTSAITQACPKVSF
AITQACPKVSFEPIP
1670
805
EnvB TVYYGVPVWKEATTT 1585 A03
Subj H (A01, A02, B52, B57, Cw6, Cw12)
EnvA MRVRGIQTSWQNLWR 191 CD8
GagB TSTLQEQIGW 75 ND CD8 B57
Subj I (A02, A31, B4901, B51, Cw7, Cw14)
EnvA IRSENITNNAKTIIV 113 CD4
EnvB
EnvB
KLWVTVYYGVPVWKE
TVYYGVPVWKEATTT
133
135
CD4
Subj J (A03, A24, B07, B18, Cw7)
EnvA AVYYGVPVWK 2300 0.345 CD8 A03
EnvA GIIGDIRQAHCHVSR 187 CD4
EnvA KQIINMWQKVGQAMY 67 CD4
EnvA
EnvA
LTVWGIKQLQARVLA
GIKQLQARVLAVERY
92
67
CD4
EnvA NYTQIIYNL 830 0.183 CD8 ND
EnvB SATEKLWVTVYYGVP 3077 CD8
EnvB TVYYGVPVWK 2245 0.0033 CD8 A03
EnvB
EnvB
CPKVSFEPIPNHYCA
SFEPIPNHYCAPAGF
257
202
EnvB RIKQIINMWQKVGKA 137 CD4
GagB RLRPGGKKKY 275 0.611 CD8 A03
*Peptide sequence used to map epitope. Where a minimum epitope was determined, the sequence is shown in bold. Where a minimum epitope is presumed based
upon the 15-mer peptide mapping and expression of the correct HLA, it is shown in bold italics. Otherwise, the individual 15-mer or two overlapping 15-mers to which
the response was mapped are shown. Responses were mapped from a time point after the rAd boost.
**Functional avidity of response to the minimum epitope expressed as the peptide concentration giving half-maximal response by ELISpot. ND = not determined.
***CD4 or CD8 phenotype of the peptide response by intracellular cytokine staining. Empty boxes = undetermined.
****HLA restriction of known or presumed minimum epitopes. ND = not determined.
*****Two digit HLA typing on the volunteers.
doi:10.1371/journal.pone.0009015.t002
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+ T cell epitopes as defined in
Table 2 are shown for four VRC 009 volunteers. Volunteer identifiers are shown in far right panels. Left panel shows the minimum epitope and
sequence variants that were tested. Left center panel shows the frequency of each variant as it occurs within HIV clades A, B, C, and D. ELISpot
responses expressed as SFCs per million PBMC at multiple peptide dilutions (mg/ml) to the epitope variants are shown from 4 weeks after the third
dose of DNA (right center panel) and 4 weeks after rAd boost (far right panel). * = only the major variant was tested due to cell limitations. ND = not
done due to absence of cells for any peptide titrations.
doi:10.1371/journal.pone.0009015.g005
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functional avidities and pattern of recognition of epitope variants
were similar in the two volunteers who generated a response to
GagTW10 (Figure 5C and D). The same was true of the responses
to EnvTK10 (Figure 5E and F). Of note is the fact that wherever
we were able to map epitopes and test for recognition of clade
variants, we routinely found broad recognition of most of the
major variants. The notable exception was the absent response to
the dominant clade A variant in GagTW10 (Figure 5C and D).
However, the responses in these two volunteers were still able to
strongly recognize the two sequences that covered the majority of
clade B, C, and D variants. Concentrating on HLA-A and B
alleles, we found that there were five HLA-A alleles and 3 HLA-B
alleles that were present more than once within our nine
volunteers. None of the mapped CD8
+ T cell responses were
restricted by HLA-A01, A02, A24, A31, B07, or B15. However,
six responses restricted by HLA-A03 and two restricted by HLA-
B57 were mapped. Every volunteer who expressed HLA-A03
(n=5) generated a response to EnvTK10 and both volunteers who
expressed HLA-B57 generated a response to GagTW10, suggest-
ing strong recognition of these two epitopes in the antigens
expressed by the vaccine.
Antibody Responses
All subjects had detectable Env-specific antibody responses
measured by ELISA (Table 3). The response was about equal to
each of the EnvA, EnvB, and EnvC glycoproteins, but responses to
Gag, Pol, and Nef were low or undetected. The median reciprocal
titer of the 14 subjects to EnvC was 6,000, which is about 100-fold
higher than the response following DNA priming (p,.001) or
following the 10
10 PU dose of rAd5 vector using historical data
(p,.001) (Figure S2). Although the DNA/rAd5 generated moder-
ately high binding antibody titers to Env, only low levels of serum
neutralizing antibody activity were observed. Sera from five subjects
neutralized selected viruses (SF162 and MW965.26) considered to
be relatively easy to neutralize (Table 3) [39,40]. Other primary
virus isolates were not neutralized by the vaccinee sera.
Discussion
We evaluated safety and HIV-specific immune responses in
healthy adult volunteers who received a priming immunization
with a 4-plasmid or 6-plasmid candidate HIV-1 DNA vaccine and
subsequently received a booster immunization with a matching
candidate HIV-1 rAd5 vaccine. This was a non-randomized,
exploratory Phase I evaluation using a roll-over design and
provided the first opportunity to boost subjects with rAd5 who had
been primed in prior studies with DNA vaccines. This small group
of rollover study participants allowed an early evaluation of the
DNA prime-rAd5 boost vaccination concept in humans. This
study focused on the detailed evaluation of vaccine-induced
immune responses. While interpretations should be tempered by
the relatively small study size, exploratory nature of the analysis,
and use of historical controls for the rAd5 only comparison, there
are a number of significant observations that merit additional
investigation. Larger studies are being conducted to provide a
more robust statistical assessment of general vaccine immunoge-
nicity, and to determine how the observations made in these
studies relate to vaccine efficacy.
Both components of the vaccine had been well-tolerated and
were immunogenic as single agents in previous Phase I clinical
trials [18,19,20]. The combination vaccine was also well-tolerated,
and the sequence of DNA priming and rAd5 vector boosting was
far more immunogenic than either the DNA or rAd5 vaccine
alone. HIV-specific T cell responses, detected by both ELISpot
and ICS were present in 100% of the subjects and were 5-fold
higher than in subjects immunized with rAd5 vector alone. The T
cell responses were (i) biased toward CD8
+ more than CD4
+; (ii)
more polyfunctional than T cell responses induced by DNA alone;
(iii) sustained for .6 months; (iv) directed against multiple epitopes
biased toward MHC class I restriction; and (v) specific for multiple
antigens (Envelope . Gag . Pol/Nef). The relative response to
Envelope antigens was also similar to that seen after DNA
immunization alone (EnvA = EnvB . EnvC). Antibody responses
were also induced in 100% of the subjects and were .100-fold
Table 3. Antibody responses induced in subjects after priming with DNA and boosting with rAd5 vaccines.
ELISA Endpoint Titer IC50 Neutralization Titer
Clade A Clade B Clade C
EnvA EnvB EnvC Gag DJ263.8 MS208.A1 RW020.02 SF162.LS HXB2 Bal.26 SS1196 MW965.26 DU156.12 Br025
12000 12000 12000 15 - - - - - - - - - -
324000 2880 12000 5760 - - - 6 - - - 10 - -
6000 2880 2880 270 - - - 16 - - - - - -
1440 270 270 15 - - - - - - - - - -
30720 30720 30720 270 - - - - - - - - - -
36000 12000 12000 15 - - - - - - - - - -
36000 6000 6000 3000 10 - - 19 - - - 4164 - -
96000 36000 48000 30 7 - - - - - - 25703 - -
12000 3750 12000 15 - - - - - - - - - -
750 150 750 15 - - - - - - - - - -
12000 3750 3750 15 - - - - - - - - - -
12000 48000 48000 750 - - - 5 - - - 103 - -
720 720 1440 15 - - - - - - - - - -
750 750 3750 15 - - - - - - - - - -
doi:10.1371/journal.pone.0009015.t003
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rAd5 vector alone. The augmented antibody response did not
have significant neutralizing activity to tier 2 viruses (Table 3) [40].
Two observations suggest that the improved response after rAd5
vector boosting was related to immunological priming by DNA.
First, the pattern of the response after rAd5 vector boost of
relatively dominant Env responses, intermediate Gag responses,
and relatively lower Pol responses was similar to that observed
after the 4-plasmid DNA immunization [20]. Secondly, multivar-
iate correlates analysis showed the response measured after DNA
priming was the best predictor of IFN-c ELISpot and CD8
+ T cell
ICS magnitude after rAd5 vector boosting. In addition, preclinical
data and recently reported human data using a different rAd5
vector suggest that augmented HIV-specific T cell responses are
not seen in subjects immunized with a second dose of rAd5 [41].
The mechanisms underlying the benefit of prior DNA
immunization are unknown. HIV-specific CD4
+ T cell responses
measured by ICS were persistent following DNA immunization,
and their presence may have aided in the rapid expansion of the
CD8
+ T cell response during boosting. Interestingly, there was no
apparent expansion of HIV-specific CD4
+ T cells following rAd5
boosting (Figure 1C). Therefore, it is equally likely that the
augmented CD8
+ T cell responses after rAd5 vector boosting were
simply a reflection of the expansion of DNA-induced CD8
+ T cell
responses. This conclusion is supported by the finding that CD8
+
T cell responses were noted in subjects immediately after DNA
priming, and that the Nef-specific responses were still detectable in
some individuals more than 2 years later. Since nef was not
included in the rAd5 vector, DNA immunization alone was
responsible for these responses. Of note, there was no difference in
the post-boost response patterns in subjects primed with 4 mg vs.
8 mg of DNA in VRC 004, which is consistent with the primary
responses measured after DNA immunization [20].
The use of heterologous platforms to initially prime and
subsequently boost an immune response has been shown to be
effective for eliciting antibody responses [42,43,44,45,46] but is
especially attractive for augmenting T cell responses [47,48,49,50].
The combination of DNA priming and recombinant viral vector
boosting has been shown to induce potent immune responses and
protection against several pathogens, including Ebola and Malaria
[51,52], and has also been shown to reduce virus load and delay
disease progression in macaques challenged with SHIV or SIV
[22,23,53]. One reason for this success may be that combining two
different modalities in a heterologous prime/boost regimen appears
to induce responses that differ from those induced by repeated
dosing of either component alone. Specifically, a recent report
showed that T cell responses to an HIV candidate vaccine
expressing Gag, Pol, and Nef in a heterologous DNA/rAd5 regimen
were different from those induced by a homologous rAd5/rAd5
regimen in humans [54]. The heterologous DNA/rAd5 induced a
greater Gag-specific CD4
+ T cell response than the homologous
rAd5/rAd5 regimen. In addition, both the Gag-specific CD4
+ and
CD8
+ T cell responses induced by DNA/rAd5 had a greater
frequency of IL-2 producing cells and more phenotypic diversity in
the DNA/rAd5-induced T cells than in those induced by rAd5/
rAd5. The homologous rAd5/rAd5 regimen also appeared to
induce a greater degree of polyfunctional T cell responses than seen
in the current study following a single dose of rAd5.
Another important consequence of using heterologous vector
combinations is to focus the immune response on the recombinant
gene product instead of the vector. Pre-existing vaccinia immunity
is known to significantly diminish the response to recombinant
replication-competent and replication-defective vaccinia-derived
vectors [42], and pre-existing adenovirus immunity has been
reported to diminish the magnitude of immune responses induced
by adenovirus vectors [18,55]. This effect potentially limits the
ability to use multiple-dose regimens of homologous vectors. DNA
immunization is not subject to anti-vector immunity and has the
potential to establish an expanded precursor frequency of antigen-
specific cellular immune responses in the majority of subjects.
Therefore, by priming with DNA or other novel vectors it may be
possible to lower the threshold for vector-based boosting of
immune responses. The impact on modifying the threshold above
which vector-based boosting occurs may be different for antibody
responses compared to T cell responses, and this question will be
addressed in future studies.
T cell subsets can be defined both by function and surface
phenotype; the protective efficacy of a vaccine might be
determined by which subsets are elicited. As we show, many of
the T cell characteristics desirable for a vaccine against HIV were
induced by DNA priming and rAd5 boosting. A high proportion
of antigen-specific CD4 and CD8 T cells express CD127,
suggesting that they are long-lived memory T cells capable of
homeostatic maintenance – substantiated by the long term stability
of the response. Further, the proportion of cells that express PD-1
declined over time (and the proportion co-expressing CD57
+ was
relatively low), consistent with maintenance of cells that can
proliferate following antigenic challenge. Finally, we observed a
mixture of TCM and TEM/TEF, providing a balance of self-
renewing cells and cells capable of a rapid effector response.
The combination of DNA priming and rAd5 boosting increased
the polyfunctionality of the vaccine-induced T cell response
(Figure 3). Although the biological significance of polyfunctional T
cell responses in humans is unknown, in vivo animal model studies
show that such qualitative immunological differences can impact
upon vaccine-elicited protection [36]. Polyfunctional cells are
thought to be more efficacious for two reasons: first, they bring to
bear, on each target cell, a wider range of effector functions
simultaneously (as opposed to requiring the simultaneous recruit-
ment of multiple effector cells). Second, each polyfunctional cell
expresses as much as an order of magnitude more of certain
effector functions (such as IFN-c or TNF; Figure S1). Ultimately,
the value of vaccine-induced immune responses, and whether they
achieve sufficient magnitude, functionality, breadth, and durability
in the right location to impact the outcome of HIV infection, can
only be determined in the setting of a clinical study evaluating
efficacy.
An efficacious T cell vaccine against HIV will need to cover the
extensive sequence diversity inherent in the current epidemic.
While there are many ways to evaluate the breadth of a T cell
response [56,57,58], we chose to take a rigorous approach by
mapping individual epitopes targeted by the vaccine-induced
response, and evaluating the ability of the epitope-specific T cells
to recognize circulating clade variants. We found that there was
wide variation in the number of epitopes targeted (1–10 epitopes,
Table 2), most were in Env and Gag (Table 2); and the T cell
responses against those epitopes recognized all or most major
clade variants (Figure 5). It is unclear whether it is better for a
vaccine to elicit multiple strain-specific T cell responses as opposed
to fewer broadly cross-reactive responses to selected epitopes in
which mutations incur a fitness cost to the virus. It is possible that
the inclusion of three separate Env antigens in the vaccine focused
the T cell response to common sequences within the three
antigens. This could have decreased the number of epitopes
targeted, but increased the likelihood of cross-clade recognition by
the response.
Epitope-specific responses may vary in their in vitro and in vivo
impact upon HIV replication [59]; a vaccine would ideally elicit
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control. Most prominent among these is the HLA B57-restricted
response to GagTW10 [12,13,60,61]. It is encouraging that this
response was elicited by the vaccine in both volunteers who
express HLA B57 (Table 2). Indeed the GagTW10 functional
avidity and pattern of clade variant recognition in these two
volunteers was similar to what has been reported in HLA B57-
expressing long-term non-progressors (Figure 5 and unpublished
results). The basis for the relative response hierarchy between
antigens (EnvA = EnvB . Gag = EnvC . Pol) is not known.
In the ‘‘Step’’ study (HVTN 502) evaluating the efficacy of
repeated homologous boosting with the Merck rAd5 vector
expressing Gag, Pol, and Nef, it was found that induction of
Gag- and Pol-specific CD8
+ T cells was not sufficient to prevent
HIV infection or result in lower set-point viral load levels in men
who became infected despite vaccination. Surprisingly, in men
who were uncircumcised or had pre-existing neutralizing antibod-
ies against Ad5, the repeated homologous rAd5 immunization
increased the risk of HIV infection above that of placebo recipients
[62]. The underlying biological mechanism for increased infection
rates is unknown, but the results have called into question the
potential role for rAd5 vectors in particular, and the value of
vaccine-induced T cell mediated immunity for HIV in general. In
contrast, a Phase III study (RV144) evaluating a recombinant
canarypox vector expressing Env, Gag, and parts of Pol and Nef
(vCP1521) in combination with a subunit glycoprotein (rgp120) in
16,402 volunteers in a general population cohort in Thailand
showed a 31.2% reduction in acquisition [63]. The failure of the
Merck rAd5 vector and partial success of the ALVAC/rgp120
prime-boost approach has highlighted the need for a greater depth
of understanding of vector biology, as well as the importance of
ongoing discovery efforts to define basic aspects of HIV immunity
and pathogenesis [64,65].
Limitations and Conclusions
The major limitation of this study was its size. Only 14 subjects
were evaluated by this intensive approach. The analysis required a
large number of PBMCs and apheresis of subjects at key time
points. The significant laboratory and personnel resources
required also limited the study size. Another limitation was that
boosting of subjects previously primed with DNA was opportu-
nistic. Therefore, the study was not randomized and the prime-
boost interval was variable. The interval was longer than that
utilized in subsequent randomized trials.
In light of the concerning outcome of the Step study and
encouraging results from the RV144 Phase III trial, it is important
to expand our understanding of effector T cell function as it relates
to HIV immunity. It will be critical to develop more sophisticated
assays for future efficacy trials to assure that antibody and T cell
functions associated with either favorable or adverse outcomes can
be defined. Better assays are needed to assess proliferative capacity
and kinetics of response, breadth and depth of response,
functionality of response including both cytolytic and noncytolytic
virus suppression activity, and localization of immune responses
beyond just the blood compartment. These approaches in
combination with more detailed assessment of antibody function,
host genetics, breakthrough viral sequences, and a systems biology
approach to analyze the transcriptional and proteomic profile
associated with HIV immunity should be applied to future
efficacy evaluations in humans to advance the goal of vaccine
development.
The 6-plasmid DNA/rAd5 vector prime-boost combination has
recently been evaluated in larger multicenter, international studies.
Based on preclinical data showing a survival benefit in SIV-
challenged macaques, favorable immunogenicity profile with
different specificity and composition than that induced by the
Merck vaccine, favorable safety profile in clinical studies to date,
design features of the rAd5 vector backbone that differ from the
Merck rAd5 vector, and the different antigen content and vaccine
schedule, the heterologous prime-boost combination of DNA/
rAd5 is being evaluated in a Phase II test-of-concept efficacy trial
designed to determine whether the frequency, magnitude,
functionality, breadth and durability of the vaccine-induced T
cell response is sufficient to impact HIV-1 infection and/or disease
progression.
Supporting Information
Table S1 Subject demographics.
Found at: doi:10.1371/journal.pone.0009015.s001 (0.04 MB
DOC)
Table S2 Subjects were monitored throughout the study with
physical and laboratory assessments by clinicians, as well as subject
self-assessment for local (pain, swelling or redness) and systemic
symptoms (fever, malaise, myalgia, headache, chills, nausea) by
diary cards for 5 days after immunization. Adverse events were
assessed for severity by using a pre-approved table using a 0–5
point grading scale and coded with the Medical Dictionary for
Regulatory Activities (MedDRA). Thirteen of 14 subjects (93%)
had ‘‘mild’’ local reactogenicity and 1 (7%) had a ‘‘moderate’’
reaction. One VRC 009 subject developed local erythema on Day
3 after the rAd5 vector boost, which peaked on Day 5 at 1667c m
and resolved by Day 9. Five subjects (36%) had no systemic
reactogenicity, 3 (21%) had mild symptoms, and 6 (43%) had
moderate systemic reactions. A common symptom complex
included malaise, headache and myalgia, sometimes with fever,
within the first 24 hours after injection as previously described
[18].
Found at: doi:10.1371/journal.pone.0009015.s002 (0.06 MB
DOC)
Table S3 Two subjects, who had previously received the 6-
plasmid DNA, had a positive HIV EIA by an Abbott commercial
diagnostic kit at the time of rAd5 vector boost; all other subjects
tested negative. By six weeks after the booster rAd5 vector
injection, all 14 subjects tested positive by the Abbott EIA; 6 (43%)
were Western blot (WB) indeterminant and 8 (57%) were WB
positive. All were confirmed uninfected by Roche RNA PCR
testing, showing that the vaccine stimulated antibody responses to
HIV gene products in approximately half of the subjects in the
absence of infection. Seropositivity persisted through 24 weeks post
rAd5 vector boost.
Found at: doi:10.1371/journal.pone.0009015.s003 (0.03 MB
DOC)
Figure S1 (A) Polyfunctional T cells are optimized for effector
function, as shown by the amount of cytokine secreted on a per-
cell basis. The top two graphs show histograms of IFN-gamma
expression from cells producing only IFN-gamma (blue), or those
that make two cytokines (green), three cytokines (orange), or four
cytokines (red). Each Polyfunctional T cell elicited by the vaccine
makes, on average, 30-fold more IFN-gamma than monofunc-
tional T cells (MFI of 57,400 vs. 1,850). (B) The distribution of
MFI for IFN-gamma (top) or TNF (bottom) showing that
polyfunctional cells are highly optimized to produce both
cytokines. MFIs were calculated only for subsets comprised of at
least 10 events; hence the limited number of data points in some
categories.
Found at: doi:10.1371/journal.pone.0009015.s004 (0.55 MB TIF)
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subjects 4 weeks after the third dose of DNA or after a single
dose of rAd5 vaccine only compared to peak response at 4–6
weeks following rAd5 vector boosting. Data for the rAd5 vaccine
only group comes from protocol VRC 006 (18). Bars represent
medians and one standard deviation.
Found at: doi:10.1371/journal.pone.0009015.s005 (0.09 MB TIF)
Diagram S1 The Consort E-Flowchart VRC 009/010 studies.
Found at: doi:10.1371/journal.pone.0009015.s006 (0.03 MB
DOC)
Checklist S1 CONSORT Checklist
Found at: doi:10.1371/journal.pone.0009015.s007 (0.19 MB
DOC)
Protocol S1 Trial Protocol
Found at: doi:10.1371/journal.pone.0009015.s008 (0.67 MB
PDF)
Protocol S2 Trial Protocol
Found at: doi:10.1371/journal.pone.0009015.s009 (0.56 MB
PDF)
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